TY - JOUR
T1 - Improvement of a mixture experiment model relating the component proportions to the size of nanonized itraconazole particles in extemporary suspensions
AU - Pattarino, Franco
AU - Piepel, Greg
AU - Rinaldi, Maurizio
N1 - Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/5/30
Y1 - 2018/5/30
N2 - A paper by Foglio Bonda et al. published previously in this journal (2016, Vol. 83, pp. 175–183) discussed the use of mixture experiment design and modeling methods to study how the proportions of three components in an extemporaneous oral suspension affected the mean diameter of drug particles (Zave). The three components were itraconazole (ITZ), Tween 20 (TW20), and Methocel® E5 (E5). This commentary addresses some errors and other issues in the previous paper, and also discusses an improved model relating proportions of ITZ, TW20, and E5 to Zave. The improved model contains six of the 10 terms in the full-cubic mixture model, which were selected using a different cross-validation procedure than used in the previous paper. Compared to the four-term model presented in the previous paper, the improved model fit the data better, had excellent cross-validation performance, and the predicted Zave of a validation point was within model uncertainty of the measured value.
AB - A paper by Foglio Bonda et al. published previously in this journal (2016, Vol. 83, pp. 175–183) discussed the use of mixture experiment design and modeling methods to study how the proportions of three components in an extemporaneous oral suspension affected the mean diameter of drug particles (Zave). The three components were itraconazole (ITZ), Tween 20 (TW20), and Methocel® E5 (E5). This commentary addresses some errors and other issues in the previous paper, and also discusses an improved model relating proportions of ITZ, TW20, and E5 to Zave. The improved model contains six of the 10 terms in the full-cubic mixture model, which were selected using a different cross-validation procedure than used in the previous paper. Compared to the four-term model presented in the previous paper, the improved model fit the data better, had excellent cross-validation performance, and the predicted Zave of a validation point was within model uncertainty of the measured value.
KW - Cross-validated regression analysis
KW - Drug nanosuspension
KW - Drug particle size
KW - Mixture experiment design
KW - Mixture experiment model
UR - http://www.scopus.com/inward/record.url?scp=85042907209&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2018.03.005
DO - 10.1016/j.ejps.2018.03.005
M3 - Article
SN - 0928-0987
VL - 117
SP - 297
EP - 300
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
ER -